TRAF2 and prostate adenocarcinoma: The results showed that patients with higher KHDC4 or TRAF2 expression levels in TCGA-PRAD data had poor PFI (KHDC4: p < 0.0001, HR = 3.233 (2.152–4.8560; TRAF2: p < 0.0001, HR = 2.389 (1.596–3.575)) and DFI prognosis values (KHDC4: p < 0.0001, HR = 7.386 (3.521–15.50); TRAF2: p < 0.0001, HR = 4.023 (1.977–8.188)) (Figure 4E).